After surveying 45 U.S. physicians that treat metastatic melanoma patients, Stifel analyst Stephen Willey said that the survey results demonstrate a “highly-favorable competitive perception” of the Phase 3 COLUMBUS data and estimated BRAF/MEK inhibitor utilization rates. Given the survey results, he is increasing his Braftovi/Mektovi peak market share and sales estimates and raised his price target on Array Biopharma shares to $26 from $24. Willey keeps a Buy rating on Array.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.